Compare CARG & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARG | IRON |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 2017 | 2020 |
| Metric | CARG | IRON |
|---|---|---|
| Price | $34.41 | $60.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $38.29 | ★ $101.67 |
| AVG Volume (30 Days) | ★ 1.6M | 942.1K |
| Earning Date | 05-22-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $316,861,000.00 | N/A |
| Revenue This Year | $11.80 | N/A |
| Revenue Next Year | $7.89 | $101.57 |
| P/E Ratio | $21.70 | ★ N/A |
| Revenue Growth | ★ 59.92 | N/A |
| 52 Week Low | $24.65 | $30.82 |
| 52 Week High | $39.42 | $99.50 |
| Indicator | CARG | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 64.11 | 35.80 |
| Support Level | $33.31 | $57.45 |
| Resistance Level | $36.23 | $65.34 |
| Average True Range (ATR) | 1.54 | 5.92 |
| MACD | 0.88 | -0.15 |
| Stochastic Oscillator | 91.54 | 59.11 |
CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. The company provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listings, through which it offers real-time and historical data analyzing the connections and pricing analysis. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two segments, namely U.S. Marketplace and Digital Wholesale. It generates maximum revenue from the U.S. Marketplace segment. Geographically, the company derives its key revenue from the United States and the rest from international markets.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.